IBDEI0D8 ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,6312,1,2,0)
 ;;=2^IV INF,HYDRATION,INIT 31-60MIN
 ;;^UTILITY(U,$J,358.3,6312,1,4,0)
 ;;=4^96360
 ;;^UTILITY(U,$J,358.3,6313,0)
 ;;=96361^^43^506^6^^^^1
 ;;^UTILITY(U,$J,358.3,6313,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6313,1,2,0)
 ;;=2^IV INF,HYDRATION,EA ADDL HR
 ;;^UTILITY(U,$J,358.3,6313,1,4,0)
 ;;=4^96361
 ;;^UTILITY(U,$J,358.3,6314,0)
 ;;=99071^^43^507^3^^^^1
 ;;^UTILITY(U,$J,358.3,6314,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6314,1,2,0)
 ;;=2^PATIENT EDUCATION MATERIALS
 ;;^UTILITY(U,$J,358.3,6314,1,4,0)
 ;;=4^99071
 ;;^UTILITY(U,$J,358.3,6315,0)
 ;;=99078^^43^507^2^^^^1
 ;;^UTILITY(U,$J,358.3,6315,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6315,1,2,0)
 ;;=2^GROUP HEALTH EDUCATION
 ;;^UTILITY(U,$J,358.3,6315,1,4,0)
 ;;=4^99078
 ;;^UTILITY(U,$J,358.3,6316,0)
 ;;=99354^^43^507^4^^^^1
 ;;^UTILITY(U,$J,358.3,6316,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6316,1,2,0)
 ;;=2^PROLONGED OTPT SVC > 30 MIN
 ;;^UTILITY(U,$J,358.3,6316,1,4,0)
 ;;=4^99354
 ;;^UTILITY(U,$J,358.3,6317,0)
 ;;=99355^^43^507^5^^^^1
 ;;^UTILITY(U,$J,358.3,6317,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6317,1,2,0)
 ;;=2^PROLONG OTPT SVC,EA ADDL 30 MIN
 ;;^UTILITY(U,$J,358.3,6317,1,4,0)
 ;;=4^99355
 ;;^UTILITY(U,$J,358.3,6318,0)
 ;;=99090^^43^507^1^^^^1
 ;;^UTILITY(U,$J,358.3,6318,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6318,1,2,0)
 ;;=2^COMPUTER DATA ANALYSIS
 ;;^UTILITY(U,$J,358.3,6318,1,4,0)
 ;;=4^99090
 ;;^UTILITY(U,$J,358.3,6319,0)
 ;;=607.84^^44^508^1
 ;;^UTILITY(U,$J,358.3,6319,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6319,1,4,0)
 ;;=4^IMPOTENCE
 ;;^UTILITY(U,$J,358.3,6319,1,5,0)
 ;;=5^607.84
 ;;^UTILITY(U,$J,358.3,6319,2)
 ;;=^270441
 ;;^UTILITY(U,$J,358.3,6320,0)
 ;;=606.9^^44^508^3
 ;;^UTILITY(U,$J,358.3,6320,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6320,1,4,0)
 ;;=4^MALE INFERTILITY NOS
 ;;^UTILITY(U,$J,358.3,6320,1,5,0)
 ;;=5^606.9
 ;;^UTILITY(U,$J,358.3,6320,2)
 ;;=^62833
 ;;^UTILITY(U,$J,358.3,6321,0)
 ;;=606.1^^44^508^4
 ;;^UTILITY(U,$J,358.3,6321,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6321,1,4,0)
 ;;=4^OLIGOSPERMIA
 ;;^UTILITY(U,$J,358.3,6321,1,5,0)
 ;;=5^606.1
 ;;^UTILITY(U,$J,358.3,6321,2)
 ;;=^85449
 ;;^UTILITY(U,$J,358.3,6322,0)
 ;;=257.2^^44^508^5
 ;;^UTILITY(U,$J,358.3,6322,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6322,1,4,0)
 ;;=4^TESTICULAR HYPOFUNC NEC
 ;;^UTILITY(U,$J,358.3,6322,1,5,0)
 ;;=5^257.2
 ;;^UTILITY(U,$J,358.3,6322,2)
 ;;=^88213
 ;;^UTILITY(U,$J,358.3,6323,0)
 ;;=302.72^^44^508^2
 ;;^UTILITY(U,$J,358.3,6323,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6323,1,4,0)
 ;;=4^MALE ERECTILE DYSFUNCTION
 ;;^UTILITY(U,$J,358.3,6323,1,5,0)
 ;;=5^302.72
 ;;^UTILITY(U,$J,358.3,6323,2)
 ;;=^73439
 ;;^UTILITY(U,$J,358.3,6324,0)
 ;;=194.0^^44^509^3
 ;;^UTILITY(U,$J,358.3,6324,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6324,1,4,0)
 ;;=4^ADRENAL TUMOR,MALIGNANT
 ;;^UTILITY(U,$J,358.3,6324,1,5,0)
 ;;=5^194.0
 ;;^UTILITY(U,$J,358.3,6324,2)
 ;;=^267298
 ;;^UTILITY(U,$J,358.3,6325,0)
 ;;=255.10^^44^509^6
 ;;^UTILITY(U,$J,358.3,6325,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6325,1,4,0)
 ;;=4^ALDOSTERONISM,PRIMARY
 ;;^UTILITY(U,$J,358.3,6325,1,5,0)
 ;;=5^255.10
 ;;^UTILITY(U,$J,358.3,6325,2)
 ;;=^330019
 ;;^UTILITY(U,$J,358.3,6326,0)
 ;;=255.14^^44^509^5
 ;;^UTILITY(U,$J,358.3,6326,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6326,1,4,0)
 ;;=4^ALDOSTERNISM,SECONDARY
 ;;^UTILITY(U,$J,358.3,6326,1,5,0)
 ;;=5^255.14
 ;;^UTILITY(U,$J,358.3,6326,2)
 ;;=^329907
 ;;^UTILITY(U,$J,358.3,6327,0)
 ;;=255.10^^44^509^14
 ;;^UTILITY(U,$J,358.3,6327,1,0)
 ;;=^358.31IA^5^2
